The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

[1]  B. Murphy,et al.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. , 2013, The Journal of infectious diseases.

[2]  G. Dayan,et al.  Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. , 2012, Vaccine.

[3]  B. Custer,et al.  Estimated cumulative incidence of West Nile virus infection in US adults, 1999–2010 , 2012, Epidemiology and Infection.

[4]  B. Murphy,et al.  A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial , 2011, PLoS neglected tropical diseases.

[5]  Majid Laassri,et al.  Microarray hybridization for assessment of the genetic stability of chimeric west nile/dengue 4 virus , 2011, Journal of medical virology.

[6]  Jerome J. Schleier,et al.  Economic Cost Analysis of West Nile Virus Outbreak, Sacramento County, California, USA, 2005 , 2010, Emerging infectious diseases.

[7]  B. Murphy,et al.  Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. , 2008, Vaccine.

[8]  E. Hayes,et al.  West Nile virus neuroinvasive disease incidence in the United States, 2002-2006. , 2008, Vector borne and zoonotic diseases.

[9]  B. Murphy,et al.  Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. , 2008, Vaccine.

[10]  B. Murphy,et al.  Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. , 2008, Vaccine.

[11]  B. Murphy,et al.  rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults , 2006, Human vaccines.

[12]  B. Murphy,et al.  Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. , 2006, Vaccine.

[13]  B. Murphy,et al.  The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers , 2006, Human vaccines.

[14]  B. Murphy,et al.  Development of a live attenuated dengue virus vaccine using reverse genetics. , 2006, Viral immunology.

[15]  T. Scott,et al.  Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors. , 2005, Vector borne and zoonotic diseases.

[16]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[17]  M. Meltzer,et al.  West Nile Virus Economic Impact, Louisiana, 2002 , 2004, Emerging infectious diseases.

[18]  B. Murphy,et al.  Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. , 2003, Vaccine.

[19]  R. Chanock,et al.  Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. , 2003, Virology.

[20]  J. Sejvar,et al.  Neurologic manifestations and outcome of West Nile virus infection. , 2003, JAMA.

[21]  J. Sejvar,et al.  Acute Flaccid Paralysis and West Nile Virus Infection , 2003, Emerging infectious diseases.

[22]  B. Murphy,et al.  A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys , 2003, Journal of Virology.

[23]  D. Vaughn,et al.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[25]  K. Hanley,et al.  Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes , 2001, Journal of Virology.

[26]  A. Barrett,et al.  Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. , 1999, Virology.

[27]  A. A. Knecht.  EVALUATION OF A , 1972 .

[28]  J. Wagner,et al.  WEST NILE VIRUS : Epidemiology and Clinical Features of an Emerging Epidemic in the United States ∗ , 2010 .

[29]  T. Monath,et al.  Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. , 2003, Advances in virus research.